National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Esketamine (Spravato®) HTA ID: 19055

Esketamine (Spravato®) in combination with a SSRI or SNRI is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current depressive episode.


NCPE Assessment Process Ongoing
Rapid review commissioned 16/12/2019
Rapid review completed 10/02/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of esketamine compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 10/02/2020
Pre-submission consultation with Applicant 30/03/2020
HTA submission received from Applicant 10/08/2020
Current status HTA submission received from Applicant